The effect of the addition of D-cycloserine to exposure sessions in the treatment of patients with obsessive-compulsive disorder.

Phase 2

Conditions: Obsessive-compulsive disorder
10002861

Registration Number: NL-OMON30642

Lead Sponsor: Meerkanten GGZ (Ermelo)

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 40

Inclusion Criteria

- Patients with a primary DSM-IV diagnosis of OCD with an age of 18 years and older as established with the Structural Clinical Interview for axis I DSM-IV Disorders (SCID I)
- Obsessive-compulsive complaints has to be such that exposure in vivo is feasible at the outpatient department, in the clinic or the direct environment.
- Patients have to understand the rationale of exposure therapy and there has to be a readiness to participate in exposure sessions.
- If a patient uses medication, dosages have to be stable (no changes in the last 2 months and during the study period).
- Negative pregnancy test (β-HCG in urine).

Exclusion Criteria

- Addiction to alcohol or drugs or abuse of these compounds
- A primary diagnosis of a personality disorder
- Psychotic disorder
- Relevant somatic disorders
- Suicidal intentions
- Pregnancy or breastfeeding
- Usage of medication possibly interfering with DCS (isoniazide, protonionamide)

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Improvement of OCD symptoms as measured by the YBOCS during and directly<br /><br>afterwards the structured ERP treatment and 1 month and 3 months later.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Assessments of the rate of anxiety and avoidance related to specific target<br /><br>symptoms.<br /><br>Also the CGI and the PADUA-R will be done.<br /><br>Response percentages (defined as minimal 30% reduction on the Y-BOCS) will be<br /><br>compared.</p><br>